Literature DB >> 7679164

Angiotensin-converting enzyme inhibition does not suppress plasma angiotensin II increase during exercise in humans.

J C Aldigier1, H Huang, F Dalmay, M Lartigue, T Baussant, A P Chassain, C Leroux-Robert, F X Galen.   

Abstract

Physical effort stimulates the reninangiotensin system (RAS). We studied the effect of an angiotensin-converting enzyme inhibitor (ACE inhibitor) in a double-blind placebo-controlled study, on eight volunteers undergoing physical stress on an ergometric bicycle. The effects of captopril (C) (50 mg, three times daily for 3 days) on arterial pressure (AP), O2 consumption (VO2), variations in auricular natriuretic factor (ANF), renin, angiotensin II (AII) plasma levels, as well as glomerular filtration rate (GFR) and microalbuminuria (MA) were evaluated. The different parameters were compared by analysis of variance (ANOVA). The pressure profile and VO2 were not modified by ACE inhibitor. Exercise stimulates release of renin; this action was greater with captopril administration (treatment effect: p < 10(-4), indicating blockade of the RAS. This inhibition was incomplete because AII levels increased markedly when captopril was given (no treatment effect: p < 0.37). Finally, ACE inhibitor resulted in decreased GFR (p = 115 +/- 5.8 ml/mn-1, C = 91.1 +/- 4, p < 0.05) with exercise without modification of MA. ACE inhibitor administration does not modify the physical performance of nonathletic subjects; AII is significantly increased with exercise despite captopril treatment; ACE inhibitor decreases GFR significantly but does not influence MA with prolonged physical effort.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7679164     DOI: 10.1097/00005344-199302000-00015

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  21 in total

Review 1.  Aetiology of running-related gastrointestinal dysfunction. How far is the finishing line?

Authors:  S M Gil; E Yazaki; D F Evans
Journal:  Sports Med       Date:  1998-12       Impact factor: 11.136

2.  Influence of angiotensin II blockade during exercise in the heat.

Authors:  K D Mittleman
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1996

Review 3.  Diverse factors influencing angiotensin metabolism during ACE inhibition: insights from molecular biology and genetic studies.

Authors:  K Morgan
Journal:  Br Heart J       Date:  1994-09

Review 4.  Aldosterone receptor blockade in the management of heart failure.

Authors:  Emiliano A Palmieri; Bernadette Biondi; Serafino Fazio
Journal:  Heart Fail Rev       Date:  2002-04       Impact factor: 4.214

5.  Does the addition of losartan improve the beneficial effects of ACE inhibitors in patients with anterior myocardial infarction? A pilot study.

Authors:  P Di Pasquale; V Bucca; S Scalzo; S Cannizzaro; A Giubilato; S Paterna
Journal:  Heart       Date:  1999-06       Impact factor: 5.994

Review 6.  Diastolic dysfunction as a cause of exercise intolerance.

Authors:  W C Little; D W Kitzman; C P Cheng
Journal:  Heart Fail Rev       Date:  2000-12       Impact factor: 4.214

Review 7.  Diastolic heart failure in the community.

Authors:  C Y Hart; M M Redfield
Journal:  Curr Cardiol Rep       Date:  2000-09       Impact factor: 2.931

8.  The serum angiotensin-converting enzyme and angiotensin II response to altered posture and acute exercise, and the influence of ACE genotype.

Authors:  David Woods; Julie Sanders; Alun Jones; Emma Hawe; Peter Gohlke; Steve E Humphries; John Payne; Hugh Montgomery
Journal:  Eur J Appl Physiol       Date:  2003-11-01       Impact factor: 3.078

Review 9.  Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial.

Authors:  B Pitt; P Chang; P B Timmermans
Journal:  Cardiovasc Drugs Ther       Date:  1995-10       Impact factor: 3.727

10.  A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction.

Authors:  Hari K Parthasarathy; Burkert Pieske; Marianne Weisskopf; Chris D Andrews; Patrick Brunel; Allan D Struthers; Thomas M MacDonald
Journal:  Eur J Heart Fail       Date:  2009-10       Impact factor: 15.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.